Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells
Open Access
- 1 January 2011
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 17 (48), 5260-6
- https://doi.org/10.3748/wjg.v17.i48.5260
Abstract
AIM: To evaluate the safety and clinical efficacy of a new immunotherapy using both α-Gal epitope-pulsed dendritic cells (DCs) and cytokine-induced killer cells. METHODS: Freshly collected hepatocellular carcinoma (HCC) tumor tissues were incubated with a mixture of neuraminidase and recombinant α1,3-galactosyltransferase (α1,3GT) to synthesize α-Gal epitopes on carbohydrate chains of the glycoproteins of tumor membranes. The subsequent incubation of the processed membranes in the presence of human natural anti-Gal IgG resulted in the effective phagocytosis to the tumor membrane by DCs. Eighteen patients aged 38-78 years with stage III primary HCC were randomLy chosen for the study; 9 patients served as controls, and 9 patients were enrolled in the study group. RESULTS: The evaluation demonstrated that the procedure was safe; no serious side effects or autoimmune diseases were observed. The therapy significantly prolonged the survival of treated patients as compared with the controls (17.1 ± 2.01 mo vs 10.1 ± 4.5 mo, P = 0.00121). After treatment, all patients in the study group had positive delayed hypersensitivity and robust systemic cytotoxicity in response to tumor lysate as measured by interferon-γ-expression in peripheral blood mononuclear cells using enzyme-linked immunosorbent spot assay. They also displayed increased numbers of CD8-, CD45RO- and CD56-positive cells in the peripheral blood and decreased α-fetoprotein level in the serum. CONCLUSION: This new tumor-specific immunotherapy is safe, effective and has a great potential for the treatment of tumorsKeywords
This publication has 26 references indexed in Scilit:
- Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical managementInternational Journal of Clinical Oncology, 2010
- A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinomaDigestive and Liver Disease, 2009
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaHepatology, 2008
- Is there a role for immunotherapy in hepatocellular carcinoma?Digestive and Liver Disease, 2006
- Nonreplicating Recombinant Vaccinia Virus Expressing CD40 Ligand Enhances APC Capacity to Stimulate Specific CD4+ and CD8+ T Cell ResponsesHuman Gene Therapy, 2005
- Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccineGynecologic Oncology, 2003
- Immune responses in cancerPharmacology & Therapeutics, 2003
- Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitopeJournal of Peptide Science, 2002
- B7-mediated costimulation and the immune responseBlood Reviews, 1996
- Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies.The Journal of Experimental Medicine, 1991